STOCK TITAN

Medicus Pharma Ltd. (MDCX) 10-K Filings

MDCX NASDAQ

Here are the 10-K annual reports from Medicus Pharma Ltd. (MDCX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.

Rhea-AI Summary

Medicus Pharma Ltd. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, governance and compensation. The filing confirms a nine‑member board with six standing committees and extensive biographies for each director and senior executive.

The company reports an aggregate market value of non‑affiliate common shares of approximately $28.3 million as of June 30, 2025, and 41,818,092 common shares outstanding as of April 15, 2026. Compensation tables disclose 2025 pay for four named executive officers, including salary, option awards and other compensation, along with option holdings and vesting values.

Rhea-AI Summary

Medicus Pharma Ltd. is a clinical-stage biotech company developing two main assets: SkinJect’s doxorubicin-containing microneedle array (D‑MNA) for non‑melanoma skin cancers and Antev’s Teverelix, a long‑acting GnRH antagonist for advanced prostate cancer and acute urinary retention.

The company completed a reverse takeover of SkinJect in 2023, listed on Nasdaq in 2024, and voluntarily delisted from the TSX Venture Exchange in 2025. As of March 17, 2026, it had 39,362,109 common shares outstanding and a non‑affiliate market value of about $28.3 million as of June 30, 2025.

SkinJect’s Phase 1 trial met safety and secondary efficacy endpoints, and a 90‑patient Phase 2 study (SKNJCT‑003) in nodular BCC has completed enrollment, with topline data showing the 200 µg dose achieving 73% clinical and 40% histological clearance at Day 57. A UAE Phase 2 trial (SKNJCT‑004) is also underway.

In August 2025, Medicus acquired 98.6% of Antev for roughly $2.97 million in cash plus 1,603,164 shares, with up to $65 million in contingent FDA milestone payments. Teverelix holds composition and process patents out to 2039 and beyond, with FDA‑cleared Phase 2b programs in both advanced prostate cancer and acute urinary retention.

Medicus maintains extensive microneedle IP licensed from the University of Pittsburgh, global Teverelix patents, and several non‑binding collaborations, including with HelixNano on mRNA‑based vaccines and Reliant AI on AI‑driven clinical development. The company has 16 full‑time employees and qualifies as an emerging growth and smaller reporting company, allowing scaled U.S. disclosure requirements.